Beam Therapeutics Inc. Common Stock (BEAM) — Analysis Summary
Beam Therapeutics Inc. Common Stock (BEAM) has a market cap of $3.20B with year-over-year revenue growth of +120.0%. Net margin stands at -57.2%. The stock trades at a P/E ratio of -49.3.
Key Takeaways
- Revenue changed +120.0% year-over-year
- Net margin of -57.2%
- P/E ratio of -49.3
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, BEAM posted revenue growth of +120.0% and trades at a P/E of -49.3.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.